{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:20:23Z","timestamp":1785792023601,"version":"3.56.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Thresholds for the minimally important difference (MID) or responder definition (RD) in health\u2010related quality\u2010of\u2010life (HRQoL) scores are required to interpret the impact of an intervention or change in the trajectory of the condition which is meaningful to patients. This study aimed to establish MID and RD for the European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma questionnaire (EORTC QLQ\u2010MY20).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A novel mixed\u2010methods approach was applied by utilizing both existing clinical trial data and prospective patient interviews. Anchor\u2010based, distribution\u2010based, and qualitative\u2010based estimates of meaningful change were triangulated to form recommended RDs for each scale of the EORTC QLQ\u2010MY20. Anchor\u2010based MIDs were summarized using weighted correlation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Recommended MIDs were as follows: Disease Symptoms (DS 10 points), Side Effects of Treatment (SE 10 points), Body Image (BI 13 points), and Future Perspective (FP 9 points). Recommended RDs were as follows: DS (16 improvement; 11 worsening), SE (6 improvement; 9 worsening), BI (33 improvement; 33 worsening), and FP (11 improvement; 11 worsening).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study generated estimates of the MID and RD for each scale of the EORTC QLQ\u2010MY20. Published estimates will enable investigators and clinicians to adopt these as standard for interpretation and for hypothesis testing. Consequently, analyses from trials of different interventions can be more comparable.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13316","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T08:10:45Z","timestamp":1566634245000},"page":"500-509","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Estimation of minimally important differences and responder definitions for EORTC QLQ\u2010MY20 scores in multiple myeloma patients"],"prefix":"10.1111","volume":"103","author":[{"given":"Kate","family":"Sully","sequence":"first","affiliation":[{"name":"Adelphi Values Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1613-8042","authenticated-orcid":false,"given":"Andrew","family":"Trigg","sequence":"additional","affiliation":[{"name":"Adelphi Values Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-9893","authenticated-orcid":false,"given":"Nicola","family":"Bonner","sequence":"additional","affiliation":[{"name":"Adelphi Values Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Moreno\u2010Koehler","sequence":"additional","affiliation":[{"name":"Adelphi Values Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Trennery","sequence":"additional","affiliation":[{"name":"Adelphi Values Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-8173","authenticated-orcid":false,"given":"Nina","family":"Shah","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks CA USA"},{"name":"University of California San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-9526","authenticated-orcid":false,"given":"Emre","family":"Yucel","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-708X","authenticated-orcid":false,"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[{"name":"Adelphi Values Cheshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9648"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.20"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4172\/1948-5956.1000430"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.185"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1198\/sbr.2011.10070"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01404.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-1055-z"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.045"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4324\/9780203056615"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074534"},{"key":"e_1_2_8_14_1","first-page":"3921","article-title":"Health related quality of life results from the open\u2010label, randomized, phase III endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"34","author":"Ludwig H","year":"2016","journal-title":"Am Soc Hematology"},{"key":"e_1_2_8_15_1","first-page":"5368","article-title":"Continued treatment duration, drug dosing and health\u2010related quality of life (HRQoL) of patients with relapsed\/refractory multiple myeloma (RRMM) receiving 2nd and 3rd line treatments: results from a European Multicentre Study","volume":"122","author":"Leleu X","year":"2013","journal-title":"Am Soc Hematology"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.9"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.002"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-1028-2"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01206.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-874396"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019117"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114468"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.03.011"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_2_8_28_1","volume-title":"Triangulating estimates of meaningful change or difference in patient\u2010reported outcomes: application of a correlation\u2010based weighting procedure","author":"Harper A","year":"2018"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015276414526"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00097-8"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2005.07.290"},{"key":"e_1_2_8_32_1","unstructured":"FDA.Document for Patient\u2010Focused Drug Development Public Workshop on Guidance 3: Select Develop or Modify Fit\u2010For\u2010Purpose. Clinical Outcome Assessments. 2018;https:\/\/www.fda.gov\/media\/116277\/download"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12070"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0163278705275340"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.11.018"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1016-5"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13316","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13316","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T01:44:34Z","timestamp":1694223874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/ejh.13316"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13316","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"2019-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}